Q3 2025 Axsome Therapeutics Inc Earnings Call Transcript
Key Points
- Axsome Therapeutics Inc (AXSM) reported strong revenue growth with total revenue of $171 million, a 63% increase year over year.
- AUVELITY, a treatment for major depressive disorder, showed impressive growth with net product sales of $136.1 million, up 69% from the previous year.
- The company successfully submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation, marking a significant milestone.
- Axsome's R&D pipeline is robust, with multiple late-stage programs and two NDA stage programs expected to progress in the coming months.
- The company ended the quarter with a strong cash position of $325.3 million, sufficient to fund operations into cash flow positivity.
- Axsome Therapeutics Inc (AXSM) reported a net loss of $47.2 million for the quarter, although this was an improvement from the previous year's loss.
- The gross to net discounts for AUVELITY and SUNOSI are expected to increase in Q4, potentially impacting net revenue.
- SYMBRAVO, despite being in its first full quarter on the market, generated only $2.1 million in net sales, indicating a slow start.
- Research and development expenses decreased by 11%, which may suggest a slowdown in new clinical trial initiations.
- The company anticipates elevated gross to net discounts for SYMBRAVO during its launch phase, which could affect profitability.
Good morning, and welcome to the Axsome Therapeutics third quarter 2025 earnings conference call. My name is Daryl, and I will be your operator for today's call. (Operator Instructions) Please note that this call is being recorded.
I would now like to hand the call over to Darren Opland, Senior Director of Corporate Communications. Please go ahead.
Thank you, Daryl. Good morning, everyone. Thank you for joining us for Axsome's third quarter 2025 earnings conference call. With us today are Dr. Herriot Tabuteau, our Chief Executive Officer; Nick Pizzie, our Chief Financial Officer; and Ari Maizel, our Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer; and Hunter Murdock, our General Counsel, will also be available for Q&A.
This morning, we issued our press release providing a business update and detailed financial results for the quarter. I encourage everyone to visit the Investors section of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
